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Lesson of the week
Useless and dangerous—fine needle aspiration of hepatic
colorectal metastases
M S Metcalfe, F H G Bridgewater, E J Mullin, G J Maddern
Fine needle aspiration cytology (FNAC) is an
established tool for diagnosing liver tumours. It has
recognised complications, however. Use of the
procedure in abdominal tumours is fatal in 0.006 to
0.031% of cases.1 2 Most deaths occur with liver
tumours and are due to haemorrhage. Another
complication is that metastases can seed along biopsy
needle tracts, although this has been reported to be
rare, with an incidence of 0.003% to 0.07%, mostly
from pancreatic tumours.1 2 More recently, much
higher rates (0.4% to 5.1%) of needle tract metastases
have been reported when FNAC is used in liver lesions,
usually for primary liver tumours.3–7
Only 13 cases of needle tract colorectal metastases
caused by FNAC in liver lesions are described in jour-
nals listed in Medline.7–13 Several authors have
commented that the procedure should be avoided
because of the risk of this complication. A further simi-
lar case is reported here, extending the contraindica-
tion of FNAC in hepatic tumours to include lesions for
which no primary malignancy has been found. There-
fore in Western populations, in which primary liver
malignancy is rare, the diagnosis of apparently
malignant liver lesions should centre on searching for
the primary tumour, rather than on FNAC of the
lesion.
Case report
A 78 year old man presenting with back pain was
found on computed tomography of his abdomen to
have a lesion in the right lobe of his liver. FNAC of the
lesion was done without referral to a surgeon, and the
result suggested metastatic adenocarcinoma. Subse-
quent investigation included colonoscopic biopsy of a
sigmoid colon tumour, which was confirmed on histol-
ogy to be the primary tumour. At laparotomy in June
2001 an anterior resection was done. The primary
tumour was Dukes’s stage C, but it was completely
excised on histology.
The liver lesion, 4 cm in diameter, was deemed
unresectable at that time as it was too close to the vena
cava. The patient was referred to an oncologist for
adjuvant chemotherapy. After chemotherapy, repeat
computed tomography showed that the lesion had
reduced substantially in size and appeared separate
from the cava and thus was amenable to surgical
resection.
In December 2001 he had a right hepatectomy. The
left lobe of the liver and the rest of the peritoneal cavity
were free of disease at operation. The metastasis was
close to but separate from the cava and was completely
excised.
The patient developed cardiac failure postopera-
tively (having a history of ischaemic heart disease) and
also a short period of decompensated hepatic failure.
He was transferred to the intensive care unit for a few
days of inotropic and appropriate hepatic support,
after which he made a slow but steady recovery and
was discharged.
In June 2002 he noted a lump under the skin in the
region of his previous FNAC puncture site and remote
from his surgical scars. The subcutaneous nodule, 1.7
cm across, was excised under local anaesthetic. Histol-
ogy showed metastatic adenocarcinoma. Despite
radiotherapy to the tumour bed the lump recurred by
October 2002. He had subsequent radical excision of
the recurrent nodule, including surrounding abdomi-
nal wall, costal cartilages, and ribs. Despite this radical
resection there were multiple tumour deposits in the
resected specimen.
It was unlikely that the resection would be curative
as the malignant cells extended to the radical resection
margin. No further chemotherapy or radiotherapy
could be given to control this recurrence. Repeated
ultrasonography and computed tomography did not
find recurrence of the disease, either in the liver or
elsewhere. Therefore it seems likely that the patient
would have remained free of disease after his hepatec-
tomy but for the FNAC biopsy performed early in the
management of his disease. The patient subsequently
died.
Discussion
Of the seven previous reports of fine needle aspiration
cytology of hepatic colorectal metastases causing
needle tract metastases, six involve only one or two
cases each and provide no indication of the rate at
which the complication occurs.7–12 The most recent
report found that for FNAC of all hepatic malignancy
there was a 3% risk of needle tract metastasis, a rate
consistent with that found in other recently reported
studies.13 For colorectal metastases specifically, the rate
was 10% (5/51 cases); four of these five patients died as
a direct result of this complication, despite radical exci-
sion of the deposits, as in this case.
The sensitivity of FNAC for detecting hepatic
malignancy has been reported as 90-93%,6 7 similar to
the diagnostic accuracy obtainable with radiological
investigations of up to 91% sensitivity.14
Clearly it is desirable to avoid a situation where
major surgery is done—only to discover that the
suspected malignant tumour in the liver is benign. The
rate at which this happens for suspected colorectal
metastases has been reported to be only two of 159
cases, or 1.9%.15
In view of the rate of needle tract metastases (10%),
the appreciable rate of false negative FNAC results
(7-10%), and the low rate ( < 2%) of benign resection
for suspected malignancy, the authors agree with the
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be avoided when hepatic colorectal metastasis are sus-
pected.
In view of the case presented, the authors strongly
recommend that hepatic colorectal metastases be diag-
nosed and treated without FNAC at all. The investiga-
tions of an undiagnosed liver lesion should not include
the procedure, but rather should be directed to detect
the primary lesion. If these are all negative, then
further investigation of the liver lesion by positron
emission spectroscopy or laparoscopic biopsy may
confirm the diagnosis without further disseminating
disease.16 17 The abdominal wall is protected from
direct contact with tumour cells by the ports used for
laparoscopy, so laparoscopic biopsy is less likely to
result in abdominal wall metastases than percutaneous
biopsy. Positron emission spectroscopymay differentiate
between benign and malignant lesions as malignant
cells take up a radiolabelled marker more avidly than
most normal tissues and so tend to “light up” on scan-
ning.
If a hepatic lesion is discovered at the same time or
after a primary colorectal malignancy is diagnosed,
and if it appears to be malignant either on imaging or
on appearances at laparotomy, then it should be
treated as such, without biopsy. If the appearances are
of a benign lesion, or are equivocal, then repeat evalu-
ation with further imaging after an interval of three
months or with positron emission spectroscopy17 may
clarify the situation. If the disease progression is so
rapid that it appeared resectable when first detected
but becomes unresectable within three months, then
the prognosis after resection would be very poor in any
event,18 so little is lost by the delay.
Conclusion
The potential benefit of FNAC in suspected liver
lesions is the confirmation of suspected metastases,
and this may be attained effectively by other investiga-
tions with less than 2% of benign lesions misdiagnosed
as metastases. This benefit is outweighed by the risks,
including the serious and often fatal complication of
needle tract metastasis and the risk of deriving false
reassurance from a false negative FNAC result.
Contributors: MSM reviewed the literature and wrote the manu-
script. FHGB provided the patients’ records and reviewed the
case report. EJM helped to review the literature and reviewed
the discussion. GJM conceived the report and reviewed the final
draft of the manuscript before submission.
Funding: No special funding.
Competing interests: None declared.
1 Fornari F, Civardi G, Cavanna L, Di Stasi M, Rossi S, Sbolli G, et al. Com-
plications of ultrasonically guided fine-needle abdominal biopsy. Results
of a multicenter Italian study and review of the literature. The Coopera-
tive Italian Study Group. Scand J Gastroenterol 1989;24:949-55.
2 Smith EH. Complications of percutaneous abdominal fine-needle biopsy.
Review. Radiology 1991;178:253-8.
3 Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from
hepatocellular cancer: is needle biopsy of the liver always necessary? Liver
Transpl 2000;6:67-72.
4 Chapoutot C, Perney P, Fabre D, Taourel P, Bruel JM, Larrey D, et al.
Needle-tract seeding after ultrasound-guided puncture of hepatocellular
carcinoma. A study of 150 patients. Gastroenterol Clin Biol 1999;23:552-6.
(In French.)
5 Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle-tract implantation
hepatocellular carcinoma: frequency and CT findings after biopsy with a
19.5-gauge automated biopsy gun. Abdom Imaging 2000;25:246-50.
6 Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, et al.
Assessment of the benefits and risks of percutaneous biopsy before sur-
gical resection of hepatocellular carcinoma. J Hepatol 2001;35:254-8.
7 Herszenyi L, Farinati F, Cecchetto A, Marafin C, de Maria N, Cardin R, et
al. Fine-needle biopsy in focal liver lesions: the usefulness of a screening
programme and the role of cytology and microhistology. Ital J Gastroen-
terol 1995;27:473-8.
8 McGrath FP, Gibney RG, Rowley VA, Scudamore CH. Cutaneous seeding
following fine needle biopsy of colonic liver metastases. Clin Radiol
1991;43:130-1.
9 Jourdan JL, Stubbs RS. Percutaneous biopsy of operable liver lesions: is it
necessary or advisable? N Z Med J 1996;109:469-70.
10 Scheele J, Altendorf-Hofmann A. Tumour implantation from needle
biopsy of hepatic metastases.Hepatogastroenterology 1990;37:335-7.
11 Goletti O, Chiarugi M, Buccianti P, Macchiarini P. Subcutaneous implan-
tation of liver metastasis after fine needle biopsy. Eur J Surg Oncol
1992;18:636-7.
12 Vergara V, Garripoli A, Marucci MM, Bonino F, Capussotti L. Colon
cancer seeding after percutaneous fine needle aspiration of liver metastasis.
J Hepatol 1993;18:276-8.
13 Ohlsson B, Nilsson J, Stenram U, Akerman M, Tranberg KG. Percutane-
ous fine-needle aspiration cytology in the diagnosis and management of
liver tumours. Br J Surg 2002;89:757-62.
14 Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic
metastases from cancers of the gastrointestinal tract by using noninvasive
imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology
2002;224:748-56.
15 Clayton RAE, Clarke DL, Currie EJ,Madhaven KK, Parks RW,Garden OJ.
Incidence of benign pathology in patients undergoing hepatic resection
for suspected malignancy. The Surgeon 2003;1:32-8.
16 Luketich JD, Schauer P, Urso K, Townsend DW, Belani CP, Cidis Meltzer
C, et al. Minimally invasive surgical biopsy confirms PET findings in
esophageal cancer. Surg Endosc 1997;11:1213-5.
17 Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of
patients evaluated by FDG-PET before hepatic resection for metastatic
colorectal carcinoma: a prospective database study. Ann Surg 2001;233:
293-9.
18 Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al.
Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
bmjlearning.com
Understanding statistics—“Is there a significant difference?”
BMJ Learning offers online learning resources to help you with
your appraisal and revalidation. These resources train and test
your skills in a variety of clinical and non-clinical topics. We aim
to publish new modules every month, and this month we have
published an interactive case history, “Understanding statistics—
‘Is there a significant difference?’”
The reporting of results of studies in which there is no
statistically significant difference between treatment and control
arms is fraught with difficulty. Such results can be reported as “no
difference,” “no significant difference,” or a “non-significant trend”
in favour of one of the arms. However, in the words of Altman
and Bland, absence of evidence is not the same as evidence of
absence. Phil Alderson has much more to say about absence of
evidence in an editorial in this issue of the BMJ.
Increasingly papers report results of trials with confidence
intervals; this is because the play of chance leads to uncertainty
surrounding the results. In simple terms the confidence interval
describes a range of possible differences between the results in
the treatment and control arms of the trial, any of which would be
compatible with the trial findings.
Our learning module (available on bmjlearning.com) explores
the use of confidence intervals in determining whether an
important difference has been excluded between the treatment
and control arms of a trial or meta-analysis. It examines the use
of nebulisers in children with acute asthma and allows you to test
and train your critical appraisal skills in an interactive format.
Kieran Walsh editorial registrar, BMJ Learning
(bmjlearning@bmjgroup.com)
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